Newton, Mass. - 27 October 2014 - Karyopharm Therapeutics Inc. has established a wholly-owned European subsidiary in Munich, Germany and appointed Ran Frenkel as Executive Vice President, Worldwide Clinical Development. Reporting to Sharon Shacham, President and Chief Scientific Officer of Karyopharm, Mr. Frenkel will be responsible for managing the new subsidiary, Karyopharm Europe GmbH.
"The establishment of this European subsidiary will provide a strong base of clinical, medical and regulatory expertise to support our registration-directed clinical studies, which are being conducted primarily in Europe and the United States, as well as in Canada and other countries," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. "With a growing team in Europe and Ran at the helm, we have the resources and support to manage our current and planned clinical trials and to build additional European infrastructure as needed."
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts.